News
AstraZeneca’s Tagrisso delivers positive results
The study demonstrated a clinically meaningful improvement in overall survival (OS), compared to the placebo among patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.